Intellectual Disability Medicine, Department of General Practice, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Department of Psychology, Maynooth University, Maynooth, Ireland.
J Appl Res Intellect Disabil. 2019 Jul;32(4):750-761. doi: 10.1111/jar.12580. Epub 2019 Feb 22.
Polypharmacy is common in people with intellectual disabilities. Using multiple medication may lead to unintended medication-related problems (MRPs). Medication review may serve as a tool to reduce MRPs. This systematic review assessed the scientific evidence for the effectiveness of medication reviews in identifying and reducing MRPs in people with intellectual disabilities.
Literature databases were searched up to August 2017. Studies were selected that included the effect of medication reviews on identifying and/or reducing MRPs in people with intellectual disabilities with no restriction of type of medication, age and level of intellectual disabilities.
The eight studies that fulfilled the inclusion criteria report that systematic medication reviews appear to assist in the identification and reduction of MRPs.
There is a lack of studies about the effect of medication reviews on identification and reduction of MRPs, especially health outcomes for people with intellectual disabilities. Further studies with long-term follow-up are needed.
智力障碍患者普遍存在多种药物治疗的情况。使用多种药物可能导致非预期的药物相关问题（MRPs）。药物审查可能是减少 MRPs 的一种手段。本系统评价评估了药物审查在识别和减少智力障碍患者 MRPs 方面的有效性的科学证据。
截至 2017 年 8 月，对文献数据库进行了搜索。选择了包括药物审查对识别和/或减少智力障碍患者 MRPs 的影响的研究，对药物类型、年龄和智力障碍程度没有限制。
八项符合纳入标准的研究报告称，系统的药物审查似乎有助于识别和减少 MRPs。
关于药物审查对识别和减少 MRPs 的影响，特别是对智力障碍患者的健康结果，研究较少。需要进行长期随访的进一步研究。
